Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland.
JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745.
Chronic kidney disease (CKD) is the 16th leading cause of years of life lost worldwide. Appropriate screening, diagnosis, and management by primary care clinicians are necessary to prevent adverse CKD-associated outcomes, including cardiovascular disease, end-stage kidney disease, and death.
Defined as a persistent abnormality in kidney structure or function (eg, glomerular filtration rate [GFR] <60 mL/min/1.73 m2 or albuminuria ≥30 mg per 24 hours) for more than 3 months, CKD affects 8% to 16% of the population worldwide. In developed countries, CKD is most commonly attributed to diabetes and hypertension. However, less than 5% of patients with early CKD report awareness of their disease. Among individuals diagnosed as having CKD, staging and new risk assessment tools that incorporate GFR and albuminuria can help guide treatment, monitoring, and referral strategies. Optimal management of CKD includes cardiovascular risk reduction (eg, statins and blood pressure management), treatment of albuminuria (eg, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers), avoidance of potential nephrotoxins (eg, nonsteroidal anti-inflammatory drugs), and adjustments to drug dosing (eg, many antibiotics and oral hypoglycemic agents). Patients also require monitoring for complications of CKD, such as hyperkalemia, metabolic acidosis, hyperphosphatemia, vitamin D deficiency, secondary hyperparathyroidism, and anemia. Those at high risk of CKD progression (eg, estimated GFR <30 mL/min/1.73 m2, albuminuria ≥300 mg per 24 hours, or rapid decline in estimated GFR) should be promptly referred to a nephrologist.
Diagnosis, staging, and appropriate referral of CKD by primary care clinicians are important in reducing the burden of CKD worldwide.
慢性肾脏病(CKD)是全球导致寿命损失的第 16 大主要原因。初级保健临床医生进行适当的筛查、诊断和管理对于预防 CKD 相关不良结局(包括心血管疾病、终末期肾病和死亡)是必要的。
CKD 定义为肾脏结构或功能的持续异常(例如肾小球滤过率[GFR]<60mL/min/1.73m2 或白蛋白尿≥30mg/24 小时)持续超过 3 个月,影响全球 8%至 16%的人口。在发达国家,CKD 最常见的病因是糖尿病和高血压。然而,不到 5%的早期 CKD 患者知晓其疾病。在被诊断患有 CKD 的患者中,包含 GFR 和白蛋白尿的分期和新的风险评估工具可以帮助指导治疗、监测和转诊策略。CKD 的最佳管理包括降低心血管风险(例如他汀类药物和血压管理)、治疗白蛋白尿(例如血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂)、避免潜在的肾毒性药物(例如非甾体抗炎药)和调整药物剂量(例如许多抗生素和口服降糖药)。患者还需要监测 CKD 的并发症,如高钾血症、代谢性酸中毒、高磷血症、维生素 D 缺乏、继发性甲状旁腺功能亢进和贫血。那些有 CKD 进展高风险(例如估计 GFR<30mL/min/1.73m2、白蛋白尿≥300mg/24 小时或估计 GFR 快速下降)的患者应及时转介给肾病医生。
初级保健临床医生对 CKD 的诊断、分期和适当转诊对于减轻全球 CKD 的负担很重要。